JPS608222A - アントラリン安定化組成物と方法 - Google Patents

アントラリン安定化組成物と方法

Info

Publication number: JPS608222A
Authority: JP; Japan
Prior art keywords: composition; anthralin; weight; surfactant; alkyl
Prior art date: 1983-06-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP59116766A

Other languages

English (en)

Japanese (ja)

Inventor

ジヨナス・シ−・テイ・ワング

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Co

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-09

Filing date

1984-06-08

Publication date

1985-01-17

1984-06-08 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1985-01-17 Publication of JPS608222A publication Critical patent/JPS608222A/ja

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 110
NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 title claims description 107
229960002311 dithranol Drugs 0.000 title claims description 107
238000000034 method Methods 0.000 title claims description 20
230000000087 stabilizing effect Effects 0.000 title description 5
-1 alkylbenzene sulfonates Chemical class 0.000 claims description 38
239000004094 surface-active agent Substances 0.000 claims description 25
239000003945 anionic surfactant Substances 0.000 claims description 21
239000003963 antioxidant agent Substances 0.000 claims description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 15
230000003078 antioxidant effect Effects 0.000 claims description 12
201000004681 Psoriasis Diseases 0.000 claims description 10
239000008346 aqueous phase Substances 0.000 claims description 10
229910019142 PO4 Inorganic materials 0.000 claims description 8
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
235000014113 dietary fatty acids Nutrition 0.000 claims description 7
239000000194 fatty acid Substances 0.000 claims description 7
229930195729 fatty acid Natural products 0.000 claims description 7
235000021317 phosphate Nutrition 0.000 claims description 7
239000006071 cream Substances 0.000 claims description 6
239000012071 phase Substances 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
239000002674 ointment Substances 0.000 claims description 5
230000000699 topical effect Effects 0.000 claims description 5
FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
108010077895 Sarcosine Proteins 0.000 claims description 4
150000008052 alkyl sulfonates Chemical class 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
229940043230 sarcosine Drugs 0.000 claims description 4
OXLXSOPFNVKUMU-UHFFFAOYSA-N 1,4-dioctoxy-1,4-dioxobutane-2-sulfonic acid Chemical class CCCCCCCCOC(=O)CC(S(O)(=O)=O)C(=O)OCCCCCCCC OXLXSOPFNVKUMU-UHFFFAOYSA-N 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
239000007764 o/w emulsion Substances 0.000 claims description 3
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 2
239000007800 oxidant agent Substances 0.000 claims description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 5
150000008051 alkyl sulfates Chemical class 0.000 claims 4
229960000878 docusate sodium Drugs 0.000 claims 3
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 3
239000000839 emulsion Substances 0.000 claims 2
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
239000000463 material Substances 0.000 claims 1
150000003871 sulfonates Chemical class 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 20
239000000499 gel Substances 0.000 description 17
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 15
235000006708 antioxidants Nutrition 0.000 description 15
238000009472 formulation Methods 0.000 description 14
239000003921 oil Substances 0.000 description 12
235000019198 oils Nutrition 0.000 description 12
150000002500 ions Chemical class 0.000 description 10
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 10
229960004889 salicylic acid Drugs 0.000 description 10
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
239000000047 product Substances 0.000 description 9
229960005070 ascorbic acid Drugs 0.000 description 8
235000010323 ascorbic acid Nutrition 0.000 description 7
239000011668 ascorbic acid Substances 0.000 description 7
230000003647 oxidation Effects 0.000 description 7
238000007254 oxidation reaction Methods 0.000 description 7
230000003902 lesion Effects 0.000 description 6
230000007774 longterm Effects 0.000 description 6
239000002245 particle Substances 0.000 description 6
239000004322 Butylated hydroxytoluene Substances 0.000 description 5
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 5
206010040880 Skin irritation Diseases 0.000 description 5
235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000007794 irritation Effects 0.000 description 5
239000008213 purified water Substances 0.000 description 5
150000003254 radicals Chemical class 0.000 description 5
231100000475 skin irritation Toxicity 0.000 description 5
230000036556 skin irritation Effects 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000000126 substance Substances 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 4
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 4
125000000129 anionic group Chemical group 0.000 description 4
150000001450 anions Chemical class 0.000 description 4
235000010385 ascorbyl palmitate Nutrition 0.000 description 4
QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 description 4
239000007857 degradation product Substances 0.000 description 4
238000002845 discoloration Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000000693 micelle Substances 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
230000006641 stabilisation Effects 0.000 description 4
238000011105 stabilization Methods 0.000 description 4
238000003860 storage Methods 0.000 description 4
239000004255 Butylated hydroxyanisole Substances 0.000 description 3
206010015150 Erythema Diseases 0.000 description 3
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 3
235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 3
239000000473 propyl gallate Substances 0.000 description 3
235000010388 propyl gallate Nutrition 0.000 description 3
229940075579 propyl gallate Drugs 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
206010013786 Dry skin Diseases 0.000 description 2
229910052770 Uranium Inorganic materials 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
150000007942 carboxylates Chemical group 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229960001577 dantron Drugs 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000037336 dry skin Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
231100000321 erythema Toxicity 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
239000007789 gas Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000011261 inert gas Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000003999 initiator Substances 0.000 description 2
239000002563 ionic surfactant Substances 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
229940056211 paraffin Drugs 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
229910000342 sodium bisulfate Inorganic materials 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
229940099259 vaseline Drugs 0.000 description 2
239000001993 wax Substances 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical compound C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000004902 Softening Agent Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
GKHOLUJNLGYFHA-UHFFFAOYSA-N [Na].CC(C)=O Chemical compound [Na].CC(C)=O GKHOLUJNLGYFHA-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229940061720 alpha hydroxy acid Drugs 0.000 description 1
150000001280 alpha hydroxy acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000006701 autoxidation reaction Methods 0.000 description 1
238000003287 bathing Methods 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000008406 cosmetic ingredient Substances 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
HRKQOINLCJTGBK-UHFFFAOYSA-L dioxidosulfate(2-) Chemical compound [O-]S[O-] HRKQOINLCJTGBK-UHFFFAOYSA-L 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
238000005187 foaming Methods 0.000 description 1
ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000008863 intramolecular interaction Effects 0.000 description 1
239000003410 keratolytic agent Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
229940100892 mercury compound Drugs 0.000 description 1
150000002731 mercury compounds Chemical class 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000010742 number 1 fuel oil Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
229940066429 octoxynol Drugs 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical group [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000001699 photocatalysis Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229940029614 triethanolamine stearate Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

JP59116766A 1983-06-09 1984-06-08 アントラリン安定化組成物と方法 Pending JPS608222A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50285283A	1983-06-09	1983-06-09
US502852		2000-02-11

Publications (1)

Publication Number	Publication Date
JPS608222A true JPS608222A (ja)	1985-01-17

Family

ID=23999686

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59116766A Pending JPS608222A (ja)	1983-06-09	1984-06-08	アントラリン安定化組成物と方法

Country Status (21)

Country	Link
JP (1)	JPS608222A (fr)
AT (1)	AT393959B (fr)
AU (1)	AU569085B2 (fr)
BE (1)	BE899874A (fr)
CH (1)	CH659945A5 (fr)
CY (1)	CY1531A (fr)
DE (1)	DE3421510A1 (fr)
DK (1)	DK163028C (fr)
ES (1)	ES8707107A1 (fr)
FI (1)	FI83837C (fr)
FR (1)	FR2547725B1 (fr)
GB (1)	GB2142534B (fr)
HK (1)	HK66490A (fr)
IE (1)	IE57562B1 (fr)
IT (1)	IT1183058B (fr)
LU (1)	LU85411A1 (fr)
NO (1)	NO171623C (fr)
NZ (1)	NZ208338A (fr)
OA (1)	OA07720A (fr)
PT (1)	PT78713A (fr)
SE (1)	SE465205B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4551480A (en) *	1983-06-21	1985-11-05	Stiefel Laboratories, Inc.	Compositions for the treatment of psoriasis
DE3413569A1 (de) *	1984-04-11	1985-10-24	Röhm Pharma GmbH, 6108 Weiterstadt	Pharmazeutisches mittel zur psoriasis-therapie
GB8729855D0 (en) *	1987-12-22	1988-02-03	Drythanol Ltd	New dithranol compositions
AT408067B (de) *	1995-03-17	2001-08-27	Gebro Pharma Gmbh	Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1070949A (en) *	1964-10-16	1967-06-07	Hyman Yarrow	Topical compositions for the treatment of psoriasis
GB1574090A (en) *	1977-07-06	1980-09-03	Drythanol Ltd	Dithranol composition for the treatment of psoriasis
DE3008805A1 (de) *	1980-03-07	1981-09-24	Paul 8501 Oberasbach Unger	Skibremse
CA1179271A (fr) *	1981-10-23	1984-12-11	Jean-Francois Grollier	Composition epaissie anhydre, stable a l'oxydation, a base d'anthraline ou de l'un de ses derives dans un support constitue d'un alkyl ester d'acide gras et d'un agent epaississant, et son utilisation dans le traitement des maladies de la peau
FR2520233A1 (fr) *	1982-01-28	1983-07-29	Oreal	Composition d'anthraline ou de l'un de ses derives dans un ester aromatique et son utilisation dans le traitement des maladies de la peau
FR2526321A1 (fr) *	1982-05-10	1983-11-10	Salomon & Fils F	Frein de ski

1984
- 1984-05-31 NZ NZ208338A patent/NZ208338A/en unknown
- 1984-06-04 FR FR8408718A patent/FR2547725B1/fr not_active Expired
- 1984-06-06 FI FI842274A patent/FI83837C/fi not_active IP Right Cessation
- 1984-06-06 ES ES533186A patent/ES8707107A1/es not_active Expired
- 1984-06-08 DE DE19843421510 patent/DE3421510A1/de not_active Withdrawn
- 1984-06-08 NO NO842326A patent/NO171623C/no unknown
- 1984-06-08 DK DK283884A patent/DK163028C/da not_active IP Right Cessation
- 1984-06-08 AU AU29237/84A patent/AU569085B2/en not_active Ceased
- 1984-06-08 IE IE1440/84A patent/IE57562B1/en not_active IP Right Cessation
- 1984-06-08 BE BE0/213108A patent/BE899874A/fr not_active IP Right Cessation
- 1984-06-08 AT AT0189784A patent/AT393959B/de not_active IP Right Cessation
- 1984-06-08 PT PT78713A patent/PT78713A/pt not_active IP Right Cessation
- 1984-06-08 GB GB08414653A patent/GB2142534B/en not_active Expired
- 1984-06-08 LU LU85411A patent/LU85411A1/fr unknown
- 1984-06-08 CH CH2813/84A patent/CH659945A5/de not_active IP Right Cessation
- 1984-06-08 JP JP59116766A patent/JPS608222A/ja active Pending
- 1984-06-08 OA OA58314A patent/OA07720A/fr unknown
- 1984-06-08 IT IT21331/84A patent/IT1183058B/it active
- 1984-06-08 SE SE8403110A patent/SE465205B/sv not_active IP Right Cessation
1990
- 1990-08-23 HK HK664/90A patent/HK66490A/xx unknown
- 1990-11-16 CY CY1531A patent/CY1531A/en unknown

Also Published As

Publication number	Publication date
FI842274L (fi)	1984-12-10
HK66490A (en)	1990-08-31
NO171623C (no)	1993-04-21
FR2547725B1 (fr)	1987-12-04
FR2547725A1 (fr)	1984-12-28
NO171623B (no)	1993-01-04
OA07720A (fr)	1985-08-30
IE841440L (en)	1984-12-09
DK163028C (da)	1992-06-09
GB2142534A (en)	1985-01-23
SE465205B (sv)	1991-08-12
IE57562B1 (en)	1992-12-16
DK283884D0 (da)	1984-06-08
PT78713A (en)	1984-07-01
FI83837C (fi)	1991-09-10
CH659945A5 (de)	1987-03-13
DK163028B (da)	1992-01-13
GB8414653D0 (en)	1984-07-11
LU85411A1 (fr)	1985-03-26
FI842274A0 (fi)	1984-06-06
AU569085B2 (en)	1988-01-21
SE8403110L (sv)	1984-12-10
SE8403110D0 (sv)	1984-06-08
NO842326L (no)	1984-12-10
DE3421510A1 (de)	1984-12-20
AU2923784A (en)	1984-12-13
AT393959B (de)	1992-01-10
GB2142534B (en)	1987-06-03
BE899874A (fr)	1984-12-10
ES533186A0 (es)	1987-07-16
NZ208338A (en)	1987-11-27
ES8707107A1 (es)	1987-07-16
DK283884A (da)	1984-12-10
ATA189784A (de)	1991-07-15
FI83837B (fi)	1991-05-31
IT1183058B (it)	1987-10-05
CY1531A (en)	1990-11-16
IT8421331A0 (it)	1984-06-08

Publication	Publication Date	Title
DE69926843T2 (de)	2006-06-22	Aktives vitamin-d3 enthaltende lotionen in form von emulsionen
US5990100A (en)	1999-11-23	Composition and method for treatment of psoriasis
DE68929377T2 (de)	2002-10-31	Topische Zubereitungen enthaltend Benzimidazol-Derivate und Benzotriazol-Derivate
PT93935B (pt)	1996-11-29	Processo para a preparacao de uma composicao farmaceutica para o tratamento topico de acne vulgar contendo cetoconazol
BR112019001081B1 (pt)	2022-06-14	Composição tópica e usos da composição
US4039664A (en)	1977-08-02	Topical griseofulvin composition and method
JP2915931B2 (ja)	1999-07-05	抗刺激性と除感作の組成物及びその使用方法
JPS6061518A (ja)	1985-04-09	ゲル状外用組成物
JPS6043329B2 (ja)	1985-09-27	乾癬治療用ジスラノ−ル組成物
JPH0338524A (ja)	1991-02-19	コルチコステロイド含有ローション剤
JPH0545569B2 (fr)	1993-07-09
JP2529571B2 (ja)	1996-08-28	皮膚刺激感抑制剤及びこれを配合してなる化粧料
US3663716A (en)	1972-05-16	Method of treating acne with benzyl alcohol
JPS608222A (ja)	1985-01-17	アントラリン安定化組成物と方法
AU674411B2 (en)	1996-12-19	Compositions for the treatment of inflammatory proliferative skin disease and their use
JPH0899889A (ja)	1996-04-16	アトピー性皮膚炎治療剤
JPS649965B2 (fr)	1989-02-21
US5034420A (en)	1991-07-23	Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant
JPH0137370B2 (fr)	1989-08-07
JPH03120230A (ja)	1991-05-22	薬効成分の経皮吸収促進剤及び経皮吸収型製剤
JPH0977655A (ja)	1997-03-25	皮膚外用剤
JPS584721A (ja)	1983-01-11	皮膚外用剤
JPH0465044B2 (fr)	1992-10-16
JP2002332237A (ja)	2002-11-22	皮膚外用剤
KR0153203B1 (ko)	1998-11-16	피부의 보습 및 각질연화 조성물